Skip to main content
NCBI home page
Immunology logoLink to Immunology
. 1997 Jan;90(1):115–120. doi: 10.1046/j.1365-2567.1997.00131.x

Inhibition of human complement by beta-glycyrrhetinic acid.

B H Kroes 1, C J Beukelman 1, A J van den Berg 1, G J Wolbink 1, H van Dijk 1, R P Labadie 1
PMCID: PMC1456728  PMID: 9038721

Abstract

Licorice, the root extract of Glycyrrhiza glabra I., is used as a medicine for various diseases. Anti-inflammatory as well as anti-allergic activities have been attributed to one of its main constituents, glycyrrhizin. These activities are mainly ascribed to the action of the aglycone, beta-glycyrrhetinic acid. beta-Glycyrrhetinic acid has a steroid-like structure and is believed to have immunomodulatory properties. To determine whether interference with complement functions may contribute to the immunomodulatory activity of beta-glycyrrhetinic acid, its effects on the classical and alternative activation pathways of human complement were investigated. We found that beta-glycyrrhetinic acid is a potent inhibitor of the classical complement pathway (IC50 = 35 microM), whereas no inhibitory activity was observed towards the alternative pathway (IC50 > 2500 microM). The anticomplementary activity of beta-glycyrrhetinic acid was dependent on its conformation, since the alpha-form was not active. It was also established that naturally occurring steroids, e.g. hydrocortisone and cortisone, did not inhibit human complement activity under similar conditions. Detailed mechanistic studies revealed that beta-glycyrrhetinic acid acts at the level of complement component C2.

Full text

PDF
115

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Amagaya S., Sugishita E., Ogihara Y., Ogawa S., Okada K., Aizawa T. Comparative studies of the stereoisomers of glycyrrhetinic acid on anti-inflammatory activities. J Pharmacobiodyn. 1984 Dec;7(12):923–928. doi: 10.1248/bpb1978.7.923. [DOI] [PubMed] [Google Scholar]
  2. Bolotin C., Morris S., Tack B., Prahl J. Purification and structural analysis of the fourth component of human complement. Biochemistry. 1977 May 3;16(9):2008–2015. doi: 10.1021/bi00628a039. [DOI] [PubMed] [Google Scholar]
  3. Capasso F., Mascolo N., Autore G., Duraccio M. R. Glycyrrhetinic acid, leucocytes and prostaglandins. J Pharm Pharmacol. 1983 May;35(5):332–335. doi: 10.1111/j.2042-7158.1983.tb02949.x. [DOI] [PubMed] [Google Scholar]
  4. FINNEY R. S., SOMERS G. F. The antiinflammatory activity of glycyrrhetinic acid and derivatives. J Pharm Pharmacol. 1958 Oct;10(10):613–620. doi: 10.1111/j.2042-7158.1958.tb10349.x. [DOI] [PubMed] [Google Scholar]
  5. Hack C. E., Hannema A. J., Eerenberg-Belmer A. J., Out T. A., Aalberse R. C. A C1-inhibitor-complex assay (INCA): a method to detect C1 activation in vitro and in vivo. J Immunol. 1981 Oct;127(4):1450–1453. [PubMed] [Google Scholar]
  6. Hayashi J., Kajiyama W., Noguchi A., Nakashima K., Hirata M., Hayashi S., Kashiwagi S. Glycyrrhizin withdrawal followed by human lymphoblastoid interferon in the treatment of chronic hepatitis B. Gastroenterol Jpn. 1991 Dec;26(6):742–746. doi: 10.1007/BF02782862. [DOI] [PubMed] [Google Scholar]
  7. Inoue H., Inoue K., Takeuchi T., Nagata N., Shibata S. Inhibition of rat acute inflammatory paw oedema by dihemiphthalate of glycyrrhetinic acid derivatives: comparison with glycyrrhetinic acid. J Pharm Pharmacol. 1993 Dec;45(12):1067–1071. doi: 10.1111/j.2042-7158.1993.tb07182.x. [DOI] [PubMed] [Google Scholar]
  8. Inoue H., Mori T., Shibata S., Koshihara Y. Modulation by glycyrrhetinic acid derivatives of TPA-induced mouse ear oedema. Br J Pharmacol. 1989 Jan;96(1):204–210. doi: 10.1111/j.1476-5381.1989.tb11801.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Joisel F., Leroux-Nicollet I., Lebreton J. P., Fontaine M. A hemolytic assay for clinical investigation of human C2. J Immunol Methods. 1983 Apr 29;59(2):229–235. doi: 10.1016/0022-1759(83)90035-2. [DOI] [PubMed] [Google Scholar]
  10. Kimura M., Watanabe H., Abo T. Selective activation of extrathymic T cells in the liver by glycyrrhizin. Biotherapy. 1992;5(3):167–176. doi: 10.1007/BF02171049. [DOI] [PubMed] [Google Scholar]
  11. Klerx J. P., Beukelman C. J., Van Dijk H., Willers J. M. Microassay for colorimetric estimation of complement activity in guinea pig, human and mouse serum. J Immunol Methods. 1983 Oct 14;63(2):215–220. doi: 10.1016/0022-1759(83)90425-8. [DOI] [PubMed] [Google Scholar]
  12. Klerx J. P., Van Dijk H., Van der Maaden W. J., Willers J. M. Analytic study of the differential anticomplementary effects of dextran sulphate and heparin in the assay for the mouse alternative pathway. Int Arch Allergy Appl Immunol. 1985;78(2):182–189. doi: 10.1159/000233882. [DOI] [PubMed] [Google Scholar]
  13. Kobayashi M., Schmitt D. A., Utsunomiya T., Pollard R. B., Suzuki F. Inhibition of burn-associated suppressor cell generation by glycyrrhizin through the induction of contrasuppressor T cells. Immunol Cell Biol. 1993 Jun;71(Pt 3):181–189. doi: 10.1038/icb.1993.20. [DOI] [PubMed] [Google Scholar]
  14. Kondo Y., Takano F. Nitric oxide production in mouse peritoneal macrophages enhanced with glycyrrhizin. Biol Pharm Bull. 1994 May;17(5):759–761. doi: 10.1248/bpb.17.759. [DOI] [PubMed] [Google Scholar]
  15. MacKenzie M. A., Hoefnagels W. H., Jansen R. W., Benraad T. J., Kloppenborg P. W. The influence of glycyrrhetinic acid on plasma cortisol and cortisone in healthy young volunteers. J Clin Endocrinol Metab. 1990 Jun;70(6):1637–1643. doi: 10.1210/jcem-70-6-1637. [DOI] [PubMed] [Google Scholar]
  16. Nakagawa H., Komorita N. Complement component C3-derived neutrophil chemotactic factors purified from exudate of rat carrageenin-induced inflammation. Biochem Biophys Res Commun. 1993 Aug 16;194(3):1181–1187. doi: 10.1006/bbrc.1993.1947. [DOI] [PubMed] [Google Scholar]
  17. Neoh S. H., Gordon T. P., Roberts-Thomson P. J. A simple one-step procedure for preparation of C1-deficient human serum. J Immunol Methods. 1984 Apr 27;69(2):277–280. doi: 10.1016/0022-1759(84)90325-9. [DOI] [PubMed] [Google Scholar]
  18. Ohuchi K., Kamada Y., Levine L., Tsurufuji S. Glycyrrhizin inhibits prostaglandin E2 production by activated peritoneal macrophages from rats. Prostaglandins Med. 1981 Nov;7(5):457–463. doi: 10.1016/0161-4630(81)90033-1. [DOI] [PubMed] [Google Scholar]
  19. Peitsch M. C., Kovacsovics T. J., Isliker H. A rapid and efficient method for the purification of the complement subcomponents C1r and C1s in zymogen form using fast protein chromatography. J Immunol Methods. 1988 Apr 6;108(1-2):265–269. doi: 10.1016/0022-1759(88)90428-0. [DOI] [PubMed] [Google Scholar]
  20. Schleimer R. P. Potential regulation of inflammation in the lung by local metabolism of hydrocortisone. Am J Respir Cell Mol Biol. 1991 Feb;4(2):166–173. doi: 10.1165/ajrcmb/4.2.166. [DOI] [PubMed] [Google Scholar]
  21. Shiki Y., Shirai K., Saito Y., Yoshida S., Mori Y., Wakashin M. Effect of glycyrrhizin on lysis of hepatocyte membranes induced by anti-liver cell membrane antibody. J Gastroenterol Hepatol. 1992 Jan-Feb;7(1):12–16. doi: 10.1111/j.1440-1746.1992.tb00927.x. [DOI] [PubMed] [Google Scholar]
  22. Takeda H., Ohta K., Niki H., Matsumoto Y., Tanaka K., Machimura H., Yagame M., Inoue W., Endoh M., Kaneshige H. Eosinophilic peritonitis responding to treatment with glycyrrhizin. Tokai J Exp Clin Med. 1991 Oct;16(3-4):183–186. [PubMed] [Google Scholar]
  23. Teelucksingh S., Mackie A. D., Burt D., McIntyre M. A., Brett L., Edwards C. R. Potentiation of hydrocortisone activity in skin by glycyrrhetinic acid. Lancet. 1990 May 5;335(8697):1060–1063. doi: 10.1016/0140-6736(90)92633-s. [DOI] [PubMed] [Google Scholar]
  24. Van Dijk H., Van Voorst J., Jankowski I. G., Imhof J. W., Kerckhaert J. A. Differential precipitation of the Clq subcomponent of the first complement component (C1) by polyethylene glycol from normal human serum and sera of patients with collagen diseases. Clin Exp Immunol. 1984 Aug;57(2):495–501. [PMC free article] [PubMed] [Google Scholar]
  25. WARD P. A., COCHRANE C. G. BOUND COMPLEMENT AND IMMUNOLOGIC INJURY OF BLOOD VESSELS. J Exp Med. 1965 Feb 1;121:215–234. doi: 10.1084/jem.121.2.215. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Walker B. R., Edwards C. R. 11 beta-Hydroxysteroid dehydrogenase and enzyme-mediated receptor protection: life after liquorice? Clin Endocrinol (Oxf) 1991 Oct;35(4):281–289. doi: 10.1111/j.1365-2265.1991.tb03537.x. [DOI] [PubMed] [Google Scholar]
  27. Wolbink G. J., Bollen J., Baars J. W., ten Berge R. J., Swaak A. J., Paardekooper J., Hack C. E. Application of a monoclonal antibody against a neoepitope on activated C4 in an ELISA for the quantification of complement activation via the classical pathway. J Immunol Methods. 1993 Jul 6;163(1):67–76. doi: 10.1016/0022-1759(93)90240-8. [DOI] [PubMed] [Google Scholar]
  28. Yamamura Y., Kawakami J., Santa T., Kotaki H., Uchino K., Sawada Y., Tanaka N., Iga T. Pharmacokinetic profile of glycyrrhizin in healthy volunteers by a new high-performance liquid chromatographic method. J Pharm Sci. 1992 Oct;81(10):1042–1046. doi: 10.1002/jps.2600811018. [DOI] [PubMed] [Google Scholar]
  29. Zhang Y. H., Isobe K., Nagase F., Lwin T., Kato M., Hamaguchi M., Yokochi T., Nakashima I. Glycyrrhizin as a promoter of the late signal transduction for interleukin-2 production by splenic lymphocytes. Immunology. 1993 Aug;79(4):528–534. [PMC free article] [PubMed] [Google Scholar]

Articles from Immunology are provided here courtesy of British Society for Immunology

RESOURCES